
    
      <Primary Purpose> Compare clinical efficacy of group treated with cell theraputic INNOCELL
      Immuncell-LC evaluated by progression free survival with that of untreated group.

      <Secondary Purpose> Compare clinical efficacy of group treated with INNOCELL Immuncell-LC, a
      drug for treating glioblastoma evaluated by overall survival, therapy reaction, EORTC
      QLQ-C30, and Karnofsky Performance Status (KPS) and that of untreated group, and evaluate
      adverse reactions, clinical pathological tests, and its safety.
    
  